The DNM1 Knockout HAP1 Polyclonal Cells product consists of a polyclonal population of HAP1 cells engineered via CRISPR/Cas9-mediated gene disruption to eliminate expression of dynamin 1, the protein encoded by DNM1. This polyclonal knockout model provides a genetically defined loss-of-function system for investigating the central role of dynamin 1 in membrane fission events and clathrin-mediated endocytosis. The near-haploid genetic background of HAP1 cells minimizes confounding effects from allelic variation, enabling robust and unambiguous interrogation of dynamin 1-dependent pathways.
HAP1 cells were originally derived from the KBM-7 chronic myeloid leukemia (CML) cell line and maintain a near-haploid karyotype, with a single copy of most chromosomes. This unique genomic architecture eliminates functional redundancy from diploid alleles, facilitating clear genotype?Cphenotype correlations in knockout experiments. The parental HAP1 line has been extensively characterized for endocytic trafficking and is widely adopted as a simplified human cell platform for genetic screens, protein interaction studies, and chemical biology assays. Its hemizygous genome makes it particularly valuable for creating loss-of-function models where complete disruption of gene function is critical for detecting subtle phenotypic changes.
Dynamin 1, a large GTPase encoded by DNM1, functions at the neck of budding clathrin-coated vesicles to catalyze membrane scission. During endocytosis, it is recruited to nascent pits through interactions with BAR domain proteins including amphiphysin, endophilin, and syndapin (PACSIN). Additionally, scaffold proteins such as SNX9, intersectin, and cortactin contribute to the assembly of the fission machinery, linking dynamin 1 to the actin cytoskeleton and the clathrin?CAP?2 complex. GTP binding triggers dynamin oligomerization into helical collars; subsequent hydrolysis drives conformational changes that constrict and sever the vesicle neck. The activity of dynamin 1 is tightly regulated by upstream signals: phosphorylation by CDK5 and dephosphorylation by calcineurin integrate neuronal activity and calcium influx, highlighting its dynamic control in synaptic vesicle recycling. This mechanistic framework places dynamin 1 at the convergence point of receptor tyrosine kinase signaling, actin dynamics, and membrane trafficking.
In the HAP1 cell context, DNM1 knockout disrupts clathrin-mediated endocytosis, making these cells an ideal system for dissecting general endocytic mechanisms independent of neuronal-specific adaptations. While dynamin 1 is prominently expressed in neurons, its universal role in receptor internalization and plasma membrane remodeling ensures broad utility of this knockout model. The near-haploid nature of HAP1 cells amplifies phenotypic effects, simplifying the interpretation of endocytosis assays, such as transferrin and EGF uptake. Furthermore, the DNM1-null background permits functional complementation studies by re?expressing wild?type or pathogenic dynamin 1 variants, enabling researchers to directly link patient?derived mutations associated with epileptic encephalopathies and intellectual disability to molecular defects in vesicle scission and receptor trafficking.
A wide range of experimental applications is supported by these polyclonal knockout cells. Western blotting and immunofluorescence with dynamin 1?specific antibodies confirm loss of target protein. The transferrin uptake assay serves as a functional readout for clathrin?mediated endocytosis, while GTPase activity assays can quantify residual dynamin activity. Co?immunoprecipitation experiments with amphiphysin, endophilin, or clathrin reveal binding partner interactions. Total internal reflection fluorescence (TIRF) microscopy enables real?time observation of vesicle dynamics at the plasma membrane. In addition, cell viability assays under stress conditions mimic pathological states. These applications position the DNM1 Knockout HAP1 Polyclonal Cells as a versatile platform for mechanistic studies of membrane trafficking, drug screening for dynamin inhibitors, and functional annotation of DNM1 mutations. For further details and technical support, please contact Ascent Research.
